Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial
Journal Title:
Haematologica
Original Publication Date:
Nov 2024
Bone Marrow Disease(s):